Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions

Nucleic Acids Research

Volumn 40, Issue 21, 2012, Pages 10765-10779

  Decker, Keith F ^a   Zheng, Dali ^a   He, Yuhong ^a   Bowman, Tamara ^a   Edwards, John R ^a   Jia, Li ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; BINDING SITE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MAPPING; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; RNA SEQUENCE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; UPREGULATION;

ANDROGENS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84870591476     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks888     Document Type: Article

References (90)

1. de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman, O.B. Jr, Saad, F. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 364, 1995-2005.
2. de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M.J., Shen, L. et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-1154.
3. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B. et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 363, 411-422.
4. Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., Oudard, S., Theodore, C., James, N.D., Turesson, I. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 351, 1502-1512. (Pubitemid 39315317)
5. Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V., Wongvipat, J., Smith-Jones, P.M., Yoo, D., Kwon, A. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787-790.
6. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G. and Sawyers, C.L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33-39. (Pubitemid 38524696)
7. Dehm, S.M. and Tindall, D.J. (2007) Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol., 21, 2855-2863. (Pubitemid 350223500)
8. Hoimes, C.J. and Kelly, W.K. (2010) Redefining hormone resistance in prostate cancer. Ther. Adv. Med. Oncol., 2, 107-123.
9. Scher, H.I. and Sawyers, C.L. (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol., 23, 8253-8261. (Pubitemid 46211563)
10. Shen, M.M. and Abate-Shen, C. (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev., 24, 1967-2000.
11. Taplin, M.E. and Balk, S.P. (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem., 91, 483-490.
12. Mendiratta, P., Mostaghel, E., Guinney, J., Tewari, A.K., Porrello, A., Barry, W.T., Nelson, P.S. and Febbo, P.G. (2009) Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol., 27, 2022-2029.
13. Tomlins, S.A., Mehra, R., Rhodes, D.R., Cao, X., Wang, L., Dhanasekaran, S.M., Kalyana-Sundaram, S., Wei, J.T., Rubin, M.A., Pienta, K.J. et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat. Genet., 39, 41-51. (Pubitemid 46026500)
14. Bolton, E.C., So, A.Y., Chaivorapol, C., Haqq, C.M., Li, H. and Yamamoto, K.R. (2007) Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev., 21, 2005-2017. (Pubitemid 47267287)
15. Jia, L., Berman, B.P., Jariwala, U., Yan, X., Cogan, J.P., Walters, A., Chen, T., Buchanan, G., Frenkel, B. and Coetzee, G.A. (2008) Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One, 3, e3645.
16. Massie, C.E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N. et al. (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. Embo J., 30, 2719-2733.
17. Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila, A., Turunen, J.P., Lundin, M., Konsti, J. et al. (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J., 30, 3962-3976.
18. Urbanucci, A., Sahu, B., Seppala, J., Larjo, A., Latonen, L.M., Waltering, K.K., Tammela, T.L., Vessella, R.L., Lahdesmaki, H., Janne, O.A. et al. (2012) Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene, 31, 2153-2163.
19. Wang, Q., Li, W., Liu, X.S., Carroll, J.S., Janne, O.A., Keeton, E.K., Chinnaiyan, A.M., Pienta, K.J. and Brown, M. (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell, 27, 380-392. (Pubitemid 47126935)
20. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M. et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
21. Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu, W., Kaikkonen, M.U., Ohgi, K.A. et al. (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature, 474, 390-394.
22. Yu, J., Mani, R.S., Cao, Q., Brenner, C.J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., Gong, Y. et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-454.
23. Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila, A., Turunen, J.P., Lundin, M., Konsti, J. et al. (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J., 30, 3962-3976.
24. Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N. et al. (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet., 44, 685-689.
25. Montgomery, R.B., Mostaghel, E.A., Vessella, R., Hess, D.L., Kalhorn, T.F., Higano, C.S., True, L.D. and Nelson, P.S. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res., 68, 4447-4454.
26. Cai, C. and Balk, S.P. (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr. Relat. Cancer, 18, R175-R182.
27. Gao, H., Ouyang, X., Banach-Petrosky, W.A., Gerald, W.L., Shen, M.M. and Abate-Shen, C. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl Acad. Sci. USA, 103, 14477-14482. (Pubitemid 44484775)
28. Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P.A., Sawyers, C.L. and Wu, H. (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res., 67, 6083-6091. (Pubitemid 47037487)
29. Mellinghoff, I.K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J. and Sawyers, C.L. (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 6, 517-527. (Pubitemid 39469987)
30. Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V.D. et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 10, 309-319. (Pubitemid 44512189)
31. Xu, K., Shimelis, H., Linn, D.E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Kong, X. et al. (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell, 15, 270-282.
32. Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D.E., Chen, H., Kong, X., Melamed, J., Tepper, C.G., Kung, H.J. et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res., 69, 2305-2313.
33. Hu, R., Dunn, T.A., Wei, S., Isharwal, S., Veltri, R.W., Humphreys, E., Han, M., Partin, A.W., Vessella, R.L., Isaacs, W.B. et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res., 69, 16-22.
34. Sun, S., Sprenger, C.C., Vessella, R.L., Haugk, K., Soriano, K., Mostaghel, E.A., Page, S.T., Coleman, I.M., Nguyen, H.M., Sun, H. et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest., 120, 2715-2730.
35. Watson, P.A., Chen, Y.F., Balbas, M.D., Wongvipat, J., Socci, N.D., Viale, A., Kim, K. and Sawyers, C.L. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA, 107, 16759-16765.
36. Thalmann, G.N., Anezinis, P.E., Chang, S.M., Zhau, H.E., Kim, E.E., Hopwood, V.L., Pathak, S., von Eschenbach, A.C. and Chung, L.W. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54, 2577-2581. (Pubitemid 24173741)
37. Thalmann, G.N., Sikes, R.A., Wu, T.T., Degeorges, A., Chang, S.M., Ozen, M., Pathak, S. and Chung, L.W. (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate, 44, 91-103. (Pubitemid 30419183)
38. Jia, L., Shen, H.C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J.K., Stanczyk, F.Z., Jones, P.A. et al. (2006) Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol. Cell. Biol., 26, 7331-7341. (Pubitemid 44477706)
39. Jia, L., Kim, J., Shen, H., Clark, P.E., Tilley, W.D. and Coetzee, G.A. (2003) Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol. Cancer Res., 1, 385-392. (Pubitemid 36437924)
40. Langmead, B., Trapnell, C., Pop, M. and Salzberg, S.L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, R25.
41. Jothi, R., Cuddapah, S., Barski, A., Cui, K. and Zhao, K. (2008) Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res., 36, 5221-5231.
42. Liang, K. and Keles, S. (2012) Detecting differential binding of transcription factors with ChIP-seq. Bioinformatics, 28, 121-122.
43. Smit, A., Hubley, R. and Green, P. (1996-2010) RepeatMasker Open-3.0.
44. Robinson, M.D., McCarthy, D.J. and Smyth, G.K. (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26, 139-140.
45. Stark, R. and Brown, G. (2012) DiffBind: Differential Binding Analysis of ChIP-Seq peak data. R package version 1.1.2.
46. Chan, P.P. and Lowe, T.M. (2009) GtRNAdb: a database of transfer RNA genes detected in genomic sequence. Nucleic Acids Res., 37, D93-D97.
47. Bailey, T.L. and Elkan, C. (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc. Int. Conf. Intell. Syst. Mol. Biol., 2, 28-36.
48. Machanick, P. and Bailey, T.L. (2011) MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics, 27, 1696-1697.
49. McLeay, R.C. and Bailey, T.L. (2010) Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data. BMC Bioinformatics, 11, 165.
50. Bryne, J.C., Valen, E., Tang, M.H., Marstrand, T., Winther, O., da Piedade, I., Krogh, A., Lenhard, B. and Sandelin, A. (2008) JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res., 36, D102-D106. (Pubitemid 351149704)
51. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods, 5, 621-628. (Pubitemid 351911867)
52. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J. and Pachter, L. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol., 28, 511-515.
53. Trapnell, C., Pachter, L. and Salzberg, S.L. (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-1111.
54. Anders, S. (2012), http://www-huber.embl.de/users/anders/HTSeq/doc/count. html (3 September 2012, date last accessed).
55. Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol., 11, R25.
56. Falcon, S. and Gentleman, R. (2007) Using GOstats to test gene lists for GO term association. Bioinformatics, 23, 257-258. (Pubitemid 46189622)
57. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-15550. (Pubitemid 41528093)
58. Planet, E. (2010) phenoTest: tools to test association between gene expression and phenotype in a way that is efficient, structured, fast and scalable. R package version 1.4.0.
59. Culhane, A.C., Schroder, M.S., Sultana, R., Picard, S.C., Martinelli, E.N., Kelly, C., Haibe-Kains, B., Kapushesky, M., St Pierre, A.A., Flahive, W. et al. (2012) GeneSigDB: a manually curated database and resource for analysis of gene expression signatures. Nucleic Acids Res., 40, D1060-D1066.
60. Jia, L., Choong, C.S., Ricciardelli, C., Kim, J., Tilley, W.D. and Coetzee, G.A. (2004) Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res., 64, 2619-2626. (Pubitemid 38523920)
61. Dekker, J., Rippe, K., Dekker, M. and Kleckner, N. (2002) Capturing chromosome conformation. Science, 295, 1306-1311. (Pubitemid 34157624)
62. Mitchell, J.A. and Fraser, P. (2008) Transcription factories are nuclear subcompartments that remain in the absence of transcription. Genes Dev., 22, 20-25.
63. Hagege, H., Klous, P., Braem, C., Splinter, E., Dekker, J., Cathala, G., de Laat, W. and Forne, T. (2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protoc., 2, 1722-1733.
64. Liu, A.Y., Brubaker, K.D., Goo, Y.A., Quinn, J.E., Kral, S., Sorensen, C.M., Vessella, R.L., Belldegrun, A.S. and Hood, L.E. (2004) Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate, 60, 98-108. (Pubitemid 38758575)
65. Sramkoski, R.M., Pretlow, T.G. 2nd, Giaconia, J.M., Pretlow, T.P., Schwartz, S., Sy, M.S., Marengo, S.R., Rhim, J.S., Zhang, D. and Jacobberger, J.W. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev. Biol. Anim., 35, 403-409. (Pubitemid 29380004)
66. Lupien, M., Eeckhoute, J., Meyer, C.A., Wang, Q., Zhang, Y., Li, W., Carroll, J.S., Liu, X.S. and Brown, M. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell, 132, 958-970. (Pubitemid 351391952)
67. Matys, V., Fricke, E., Geffers, R., Gossling, E., Haubrock, M., Hehl, R., Hornischer, K., Karas, D., Kel, A.E., Kel-Margoulis, O.V. et al. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res., 31, 374-378. (Pubitemid 36150406)
68. Newburger, D.E. and Bulyk, M.L. (2009) UniPROBE: an online database of protein binding microarray data on protein-DNA interactions. Nucleic Acids Res., 37, D77-D82.
69. Zhao, J.C., Yu, J., Runkle, C., Wu, L., Hu, M., Wu, D., Liu, J.S., Wang, Q. and Qin, Z.S. (2012) Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res., 22, 322-331.
70. He, H.H., Meyer, C.A., Shin, H., Bailey, S.T., Wei, G., Wang, Q., Zhang, Y., Xu, K., Ni, M., Lupien, M. et al. (2010) Nucleosome dynamics define transcriptional enhancers. Nat. Genet., 42, 343-347.
71. Li, G., Ruan, X., Auerbach, R.K., Sandhu, K.S., Zheng, M., Wang, P., Poh, H.M., Goh, Y., Lim, J., Zhang, J. et al. (2012) Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell, 148, 84-98.
72. Varambally, S., Yu, J., Laxman, B., Rhodes, D.R., Mehra, R., Tomlins, S.A., Shah, R.B., Chandran, U., Monzon, F.A., Becich, M.J. et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8, 393-406. (Pubitemid 41579834)
73. Stanbrough, M., Bubley, G.J., Ross, K., Golub, T.R., Rubin, M.A., Penning, T.M., Febbo, P.G. and Balk, S.P. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., 66, 2815-2825.
74. Sedelaar, J.P. and Isaacs, J.T. (2009) Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate, 69, 1724-1729.
75. Ang, J.E., Olmos, D. and de Bono, J.S. (2009) CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer, 100, 671-675.
76. Attard, G., Reid, A.H., Olmos, D. and de Bono, J.S. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res., 69, 4937-4940.
77. Attard, G., Reid, A.H., A'Hern, R., Parker, C., Oommen, N.B., Folkerd, E., Messiou, C., Molife, L.R., Maier, G., Thompson, E. et al. (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol., 27, 3742-3748.
78. Titus, M.A., Schell, M.J., Lih, F.B., Tomer, K.B. and Mohler, J.L. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res., 11, 4653-4657. (Pubitemid 41557182)
79. Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Chieffo, N., Smith, L.A., Karlou, M. et al. (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol., 30, 637-643.
80. Hofland, J., van Weerden, W.M., Dits, N.F., Steenbergen, J., van Leenders, G.J., Jenster, G., Schroder, F.H. and de Jong, F.H. (2010) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res., 70, 1256-1264.
81. Lamont, K.R. and Tindall, D.J. (2011) Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol. Endocrinol., 25, 897-907.
82. Jariwala, U., Prescott, J., Jia, L., Barski, A., Pregizer, S., Cogan, J.P., Arasheben, A., Tilley, W.D., Scher, H.I., Gerald, W.L. et al. (2007) Identification of novel androgen receptor target genes in prostate cancer. Mol. Cancer, 6, 39.
83. Chen, H., Libertini, S.J., George, M., Dandekar, S., Tepper, C.G., Al-Bataina, B., Kung, H.J., Ghosh, P.M. and Mudryj, M. (2010) Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr. Relat. Cancer, 17, 857-873.
84. Chepelev, I., Wei, G., Wangsa, D., Tang, Q. and Zhao, K. (2012) Characterization of genome-wide enhancer-promoter interactions reveals co-expression of interacting genes and modes of higher order chromatin organization. Cell Res., 22, 490-503.
85. Dehm, S.M. and Tindall, D.J. (2006) Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J. Biol. Chem., 281, 27882-27893. (Pubitemid 44414500)
86. Gregory, C.W., Johnson, R.T. Jr, Mohler, J.L., French, F.S. and Wilson, E.M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 61, 2892-2898. (Pubitemid 32691931)
87. Gioeli, D. and Paschal, B.M. (2012) Post-translational modification of the androgen receptor. Mol. Cell. Endocrinol., 352, 70-78.
88. Gupta, S., Stamatoyannopoulos, J.A., Bailey, T.L. and Noble, W.S. (2007) Quantifying similarity between motifs. Genome Biol., 8, R24.
89. Saxonov, S., Berg, P. and Brutlag, D.L. (2006) A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA, 103, 1412-1417. (Pubitemid 43191179)
90. Smyth, G.K. (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, Article3.